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Abstract: The discovery of anticancer activity in cisplatin triggered the development of novel drugs containing metals such as platinum or
ruthenium. Extremely diverse structural chemistry and the interaction of metal complexes with biomolecules resulted in the exploration
of novel metal complexes with drug potential. In the present study, the anticancer and cytotoxic activities and the mechanisms of action
were investigated for C16H34N8O5Ag2Cd (AN1) and C11H16N7O2Ag3Ni (AN7), 2 newly synthesized dicyanidoargentate(I) complexes.
The anticancer and cytotoxic activities of AN1 and AN7 on several cancer cell lines were tested by cell proliferation and cytotoxic
activity assays, respectively. The apoptotic and replication inhibitory potentials of the compounds were investigated using terminal
deoxynucleotidyl transferase dUTP nick and labeling (TUNEL) and DNA topoisomerase inhibition assays. AN1 and AN7 showed
significant (P < 0.05) anticancer activity and lower cytotoxicity against all cell lines tested. The TUNEL assay results indicated that AN1
and AN7 may inhibit cell proliferation by inducing apoptosis. The compounds showed very significant DNA topoisomerase I inhibitory
activity. Based on the results, it is suggested that compounds AN1 and AN7 are potential anticancer drug candidates.
Key words: Metal complexes, anticancer activity, cytotoxic activity, apoptosis

1. Introduction
Cancer is considered the second most common disease
causing death (Tuncer, 2008). It is estimated that 19.3
million new cancer cases will be detected per year by 2025.
The incidence, morbidity, and mortality of cancer are
expected to be much higher in developing countries such
as Turkey. Efforts to cure cancer or reduce its occurrence
will be significantly important (Tuncer, 2008).
Although many anticancer drugs have been used to
treat cancer, they have some limitations, such as side effects,
tumor specificity, and tumor cell resistance (Roche, 2002).
Therefore, new anticancer drug candidates with few or no
side effects need to be developed as alternatives to current
chemotherapeutic drugs. Metals and metal compounds
have been used in medicine as antiprotozoal, antiulcer,
antiarthritic, antimalarial, antimicrobial, and anticancer
drugs (Avendańo, 2008). Nowadays, the application
of metal complexes in medicine is being investigated
very extensively. Thati et al. (2007) reported that silver
complexes of coumarin derivatives possess anticancer
activity against certain types of cancer. Zhu et al. (2003)
reported that silver carboxylate dimers exert anticancer
activity against human carcinoma cells. The phosphine
* Correspondence: sabant@yahoo.com
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complexes of silver have been shown to possess anticancer
activity (Liu et al., 2008).
The discovery of the anticancer potential of cisplatin
(Kelland et al., 2007) triggered the development of novel
metallodrugs. Several platinum- or ruthenium-based
metal coordination complexes such as carboplatin,
oxaplatin, and NAMI-1 have been used or have been under
trial as anticancer drugs (Gielen and Tiekink, 2005). The
extremely diverse structural chemistry and interactions of
metal complexes with biomolecules such as nucleic acids
and proteins have resulted in the exploration of anticancer
activities of other metal coordination complexes.
Various silver compounds with interesting antitumor
activity have been reported previously. Zachariadis et
al. (2004) determined the anticancer activity of silver(I)
complexes of heterocyclic thioamide 2-mercapto-3,4,5,6tetrahydropyrimidine derivatives against certain types
of cancer. In addition, El-Din et al. (2011) reported
the anticancer activity of [SnMe3(1,2-bis(4-pyridyl)
ethane)][Ag(CN)2].2H2O against human carcinoma
cells. In particular, silver complexes have been found to
be promising alternatives to current anticancer drugs
lacking activity against various cancer types. Serious
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limitations have prompted many researchers to develop
alternative strategies to treat cancer based on different
metal complexes.
In the present study, 2 silver complexes, [Cd2(edbea)2]
[Ag(CN)2]2.H2O (AN1) and [Ni(N-bishydeten)Ag3(CN)5]
(AN7), were successfully synthesized and tested for
their anticancer and cytotoxic activities against C6 (rat
brain tumor), HeLa (human cervical cancer), HT29
(human colon cancer), and Vero (African green monkey
kidney) cell lines. The solutions were made in a tube with
concentrations ranging from 5 to 100 µg/mL for each
compound. The antiproliferative and apoptotic activities
of these compounds and ligand [Ag(CN)2]1 on cancer
cell lines were screened using BrdU cell proliferation
assay (BCPA) and DNA laddering assay, respectively.
5-Fluorouracil (5FU) was used as a standard compound.
According to the BCPA test results, these compounds
and ligand exhibited very high antiproliferative effects on
cancer cells, whereas 5FU had very low antiproliferative
effects with the same administered dose. Another goal was
testing for cytotoxic or cytostatic activity in vitro against
cancer cell lines. An ideal anticancer drug would destroy
cancer cells without harming normal cells. The cytotoxic
activities of these compounds and ligand were evaluated
by lactate dehydrogenase (LDH) assay. Any compound
that has cytotoxic effects may induce necrosis, in which
cells lose membrane integrity and die rapidly as a result of
cell lysis, or the cells can activate apoptosis. In LDH tests,
these compounds showed the same cytotoxic effects as
5FU, whereas the ligand revealed higher cytotoxic effects
than 5FU on cancer cell lines in a dose-dependent manner
(P < 0.05).
The antiproliferative activities of these compounds
on cancer cell lines were also screened using terminal
deoxynucleotidyl transferase dUTP nick and labeling
(TUNEL) assay and topoisomerase I assay. The results
of the TUNEL assay indicated that the novel complexes
may inhibit cell proliferation through the induction of
apoptosis. Based on initial experiments, these compounds
were selected for further preclinical development due to a
potent antitopoisomerase I feature. The results indicated
that the ligand does not have cytostatic activity, but the
compounds do have such activity. In conclusion, the results
demonstrated that these compounds possess favorable
qualities as anticancer agents. Nevertheless, further studies
are required to show effectiveness in animal models.
2. Materials and methods
2.1. Synthesis of [Cd2(edbea)2][Ag(CN)2]2.H2O (AN1)
and [Ni(N-bishydeten)Ag3(CN)5] (AN7)
Edbea
(2,2′-(ethylenedioxy)bis(ethylamine))
and
N-bishydeten (N,N-bis(2-hydroxyethyl) ethylenediamine)
were used as ligands that can coordinate to a metal ion (Ni

or Cd) through their donor atoms. Dicyanidoargentate
{[Ag(CN)2]-} is a linear anion of considerable stability and
simplicity. The novel complexes [Cd2(edbea)2][Ag(CN)2]2.
H2O (AN1) and [Ni(N-bishydeten)Ag3(CN)5] (AN7)
were successfully synthesized as described by Korkmaz
(2014). AN1 was obtained at a yield of 62%. The elemental
analysis calculated (%) for C16H34N8O5Ag2Cd indicated C
25.74, H 4.59, N 15.01, and the following were found: C
26.53, H 5.66, N 16.08. IR spectra (KBr disk cm–1) 3631
[υ(O–H)]; 3378, 3336, 3282 [υ(N–H)]; 2923, 2877, 2897
[υ(C–H)]; 2154 [υ(C≡N)]; 1587 [δ(N–H)]; 1743 [δ(CH2)];
1101 [υ(C-N)]; 1033 [υ(C-O)]. AN7 was obtained at a
yield of 35%. The elemental analysis calculated (%) for
C11H16N7O2Ag3Ni indicated C 20.00, H 2.44, N 14.84,
and the following were found: C 19.68, H 2.14, N 14.78.
IR spectra (KBr disk cm–1) 3596 [υ(O–H)]; 3336, 3280,
3191 [υ(N–H)]; 2979, 2904, 2861 [υ(C–H)]; 2163, 2129
[υ(C≡N)]; 1602 [δ(N–H)]; 1452 [δ(CH2)]; 1197 [υ(C-N)];
1031 [υ(C-O)].
2.2. Cell culture
C6, HT29, HeLa, and Vero cell lines (American Type
Culture Collection, USA) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM, Sigma, Germany)
supplemented with 10% (v/v) fetal bovine serum (Sigma)
and PenStrep solution (10,000 U/10 mg) (Sigma) (Murphy
et al., 2009; Yoshimoto et al., 2012). At confluence, cells
were detached from the flasks using 4 mL of trypsinEDTA (Sigma) and centrifuged, and the cell pellet was
resuspended with 4 mL of supplemented DMEM.
2.3. Cell proliferation assay
A cell suspension containing 3 × 103 cells in 100 µL
was pipetted into the wells of 96-well cell culture plates
(COSTAR, Corning, USA). The test compounds (AN1,
AN7, and [Ag(CN)2]1-) and a positive control compound
(5FU) were dissolved in sterile dimethyl sulfoxide (DMSO).
The amount of DMSO was adjusted to 0.5% maximum.
The cells were treated with AN1, AN7, [Ag(CN)2]1-, and
5FU at final concentrations of 5, 10, 20, 30, 40, 50, 75,
and 100 µg/mL. Cell controls and solvent controls were
treated with supplemented DMEM and sterile DMSO,
respectively. The final volume of the wells was adjusted to
200 µL by supplemented DMEM.
The cells were then incubated at 37 °C with 5% CO2
overnight. The antiproliferative activity of the compounds
was determined using a BrdU cell proliferation enzymelinked immunosorbent assay (ELISA) kit according to the
manufacturer’s protocol (Roche, USA) for a calorimetric
immunoassay based on BrdU incorporation into the
cellular DNA. Briefly, cells were exposed to BrdU labeling
reagent for 4 h, followed by fixation in FixDenat solution
for 30 min at room temperature. Cells were then cultured
with a 1:100 dilution of anti-BrdU-POD for 90 min at
room temperature. Substrate solution was added to each
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well, and BrdU incorporation was measured at 450–650
nm using a microplate reader (Rayto, China). Each
experiment was repeated at least 3 times for each cell line.
2.4. Calculation of IC50 and % inhibition
IC50 represents the concentration of an agent that is
required for 50% inhibition in vitro. The half maximal
inhibitory concentration (IC50) of the test and control
compounds was calculated using XLfit5 software (IDBS)
and expressed in µg/mL at 95% confidence intervals. The
cell proliferation assay results were reported as the percent
inhibition of the test and control substances. The percent
inhibition was calculated according to the following
formula: % inhibition = [1 - (absorbance of treatments /
absorbance of DMSO) × 100].
2.5. Cytotoxic activity assay
The cytotoxicity of AN1, AN7, [Ag(CN)2]1-, and 5FU on
C6, HT29, HeLa, and Vero cells was determined with
a LDH cytotoxicity detection kit (Roche) based on the
measurement of LDH activity released from the cytosol
of damaged cells into the supernatant according to
manufacturer’s instructions. Briefly, 3 × 104 cells in 100
µL were seeded into 96-well microtiter plates as triplicates
and treated with IC50 concentrations of AN1, AN7, and the
ligand as described above at 37 °C with 5% CO2 overnight.
LDH activity was determined by measuring absorbance at
492–630 nm using a microplate reader.
2.6. TUNEL assay
In vitro detection of apoptosis was assessed using a
TUNEL assay kit (Roche) according to the manufacturer’s
protocol. HT29 cell lines (30,000 cells/well) were placed
in a poly-L-lysine covered chamber slide. The cells were
treated with the IC50 concentrations of AN1 and AN7 and
left for 24 h of incubation. There were 2 controls for this
assay: a positive control that had DNase I treatment, and
a negative control that had no terminal deoxynucleotidyl
transferase (TdT).
When the incubation time was over, the chamber
was removed from the slide and washed with Dulbecco’s
phosphate buffered saline (DPBS) to remove the medium
and unattached cells. All of the incubation and washing
steps were done in a plastic jar. Slides were gently washed
with DPBS, and, for fixation, 4% paraformaldehyde in
DPBS at pH 7.4 was freshly prepared and added to the slides
for 60 min at room temperature. Following incubation,
the slides were washed twice with DPBS. The cells were
blocked with freshly prepared 3% H2O2 in methanol for 10
min at room temperature. Following incubation, the slides
were washed twice with DPBS.
The cells were permeabilized by prechilled 0.1%
Triton X-100 and freshly prepared 0.1% sodium citrate
in water and then incubated for 2 min on ice. All the
slides were washed with DPBS twice for 5 min each. At

950

this point, in order to prepare a DNase I enzyme-treated
positive control, 100 µL of DNase I buffer was added to
the slide and incubated at room temperature for 10 min.
Fixative cells were transferred into a TUNEL reaction
mixture (50 µL/section) containing TdT and fluoresceindUTP. Intracellular DNA fragments were then labeled by
exposing the cells to the TUNEL reaction mixture for 1 h
at 37 °C in a humidified atmosphere, protected from light.
After washing with DPBS twice, cells positive for apoptosis
showed a green fluorescent signal and were visualized by
a Leica fluorescent microscope (Leica DMIL LED Fluo,
Germany).
2.7. DNA topoisomerase I inhibition assay
The DNA topoisomerase I inhibitory activities of AN1
and AN7 were evaluated using a cell-free topoisomerase
I assay kit (TopoGen, USA). The principle of the assay
is to measure the conversion of supercoiled pHOT1
plasmid DNA to its relaxed form in the presence of DNA
topoisomerase I alone and with test compounds. The
supercoiled substrate (pHOT1 plasmid DNA) and its
relaxed product can easily be distinguished in agarose
gel, because the relaxed isomers migrate more slowly
than the supercoiled isomer. In brief, 20 µL of reaction
mixture containing 1 µL of plasmid pHOT1 DNA in
relaxation buffer was incubated with 2 U of recombinant
human topoisomerase I enzyme in the presence of IC50
concentrations of C1, C2, or camptothecin as a positive
control. The reactions were carried out at 37 °C for 30
min and then terminated by the addition of stop solution.
After the termination, the sample was analyzed using 1%
agarose gel at 4 V/cm for 60 min. After electrophoresis,
DNA bands were stained with ethidium bromide (1 mg/
mL) solution and photographed with a gel imaging system
(UVP BioSpectrum, Germany).
2.8. Statistical analysis
The statistical significance of differences was determined
by one-way analysis of variance (ANOVA) tests. Post hoc
analyses of group differences were performed using the
Tukey test, and the levels of probability were noted. SPSS
for Windows was used for statistical analyses. The results
are reported as the mean values ± standard error of the
mean (SEM) of 3 independent assays, and differences
between groups were considered to be significant at P <
0.05.
3. Results
3.1. Anticancer activity of AN1, AN7, and [Ag(CN)2]1against HT-29, HeLa, C6, and Vero cell lines
The anticancer activities of AN1, AN7, [Ag(CN)2]1-, and
5FU against HT-29, HeLa, C6, and Vero cell lines were
determined using a BrdU cell proliferation ELISA kit (Figure
1). [Ag(CN)2]1- was the most antiproliferative compound

AYDIN et al. / Turk J Biol
5-FU

AN1

AN7

[Ag(CN)2]¯

80
HT29

60
40
20

AN7

[Ag(CN)2]¯

80
C6

60
40
20

0

0
0

5

5-FU

10

20

AN1

30

40 50 75 100
Concentration (μg/mL)
AN7

0

[Ag(CN)2]¯

80

80

% Inhibition

100

HeLa

60
40

5

5-FU
100

% Inhibition

AN1

100
% Inhibition

% Inhibition

100

5-FU

10

20

30

AN1

40 50 75 100
Concentration (μg/mL)
AN7

[Ag(CN)2]¯

Vero

60
40
20

20

0

0
0

5

10

20

30 40 50 75 100
Concentration (μg/mL)

0

5

10

20

30

40 50 75 100
Concentration ( μg/mL)

Figure 1. Antiproliferative activity of AN1, AN7, [Ag(CN)2]1-, and positive control compound (5FU) on HeLa, HT29, C6, and Vero cell lines. Cell proliferation was measured using a BrdU cell ELISA assay kit. Percent inhibition was
reported as mean value ± SEM of 3 independent assays (P < 0.05).

tested on all cell lines (P < 0.01), but it was found to be
significantly toxic to the cells at concentrations of 5 µg/mL
and higher (Figure 1). [Ag(CN)2]1- was necrotic to cells,
which may lead to rapid cell-membrane disintegration.
AN1 and AN7 showed significantly (P < 0.05) higher
antiproliferative activity than 5FU against the cancer cell
lines tested, especially at high concentrations. Moreover,
AN1 and AN7 were not necrotic to cells. In contrast to
the cancer cell lines, the antiproliferative activities of the
compounds were lower on nontumorigenic Vero cells
(Figure 1). The data from the experiments suggest that the
IC50 concentrations of AN1, AN7, the Ag ligand, and 5FU
were 29.89, 65.15, 1.13, and 20.76 µg/mL for HeLa; 24.15,
70.39, 1.05, and 22.55 µg/mL for C6; 25.56, 56.09, 1.02, and
21.52 µg/mL for HT29; and 27.62, 58.19, 1.20, and 23.12
µg/mL for Vero, respectively.
3.2. Cytotoxic activity of AN1, AN7, [Ag(CN)2]1-, and
5FU on HT-29, HeLa, C6, and Vero cell lines
The cytotoxic activities of AN1, AN7, [Ag(CN)2]1-,
and 5FU on HeLa, HT29, C6, and Vero cell lines were
tested using an LDH cytotoxicity assay kit. In contrast
to the high cytotoxicity of the ligand on the cell lines,

the cytotoxicities of AN1 and AN7 were close to the
cytotoxicity of 5FU at their IC50 concentrations (Figure 2).
The percent cytotoxicity of AN1, AN7, and 5FU ranged
from 15% to 25%, whereas [Ag(CN)2]1- showed about
60% cytotoxicity (P < 0.05) against all cell lines (Figure
2). The results from the LDH assay were consistent with
cell viability regarding the IC50 concentrations of AN1 and
AN7. Therefore, it is suggested that these compounds may
have cytostatic potential rather than cytotoxic potential.
The significantly lower cytotoxicity of AN1 and AN7
than [Ag(CN)2]1 alone may indicate that the cytotoxicity
of [Ag(CN)2]1- decreases to safe levels when complexed
with (2,2′-(ethylenedioxy)bis(ethylamine)) and (N,Nbis(2-hydroxyethyl) ethylenediamine) in AN1 and AN7,
without reducing their antiproliferative potential.
3.3. Determination of apoptotic potential of AN1 and
AN7
The apoptotic potential of AN1 and AN7 on HT29 cell
lines was tested by TUNEL assay. As shown in Figure 3,
AN1, AN7, and DNase I (PC, positive control) treated
cells showed green fluorescence, indicating the fragmented
DNA in apoptotic cells (A-AN1, B-AN7, and D-PC),
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Figure 2. Cytotoxic activity of AN1, AN7, [Ag(CN)2]1-, and
positive control compound (5FU) on HeLa, HT29, C6, and Vero
cell lines. Cell lines were incubated with IC50 concentrations
of test and control compounds for 24 h, and cytotoxicity was
determined by LDH cytotoxicity assay kit. IC50 concentrations
of AN1, AN7, and ligands Ag and 5FU were 29.89, 65.15, 1.13,
and 20.76 µg/mL for HeLa; 24.15, 70.39, 1.05, and 22.55 µg/mL
for C6; 25.56, 56.09, 1.02, and 21.52 µg/mL for HT29; and 27.62,
58.19, 1.20, and 23.12 µg/mL for Vero, respectively. Percent
cytotoxicity was reported as mean value ± standard deviation of
3 independent assays (P < 0.05).

whereas the DMSO control was TUNEL-negative (C-NC).
Phase-contrast images of the HT29 cancer cells (A′-AN1,
B′-AN7, C′-NC (negative control), and D′-PC (positive
control)) also overlapped the fluorescence images of the
HT29 cancer cells. The TUNEL method indicated the
presence of apoptosis in the HT29 cell line with treatments
of 25.56 µg/mL for AN1 and 56.09 µg/mL for AN7 for 24
h. As in the case of image analysis, AN1 and AN7 caused
more apoptosis in HT29 cells than the positive control.
3.4. Detection of DNA topoisomerase I inhibitory activity
The DNA topoisomerase I inhibitory activities of AN1
and AN7 were determined by DNA topoisomerase I
inhibition assay. As shown in Figure 4, both compounds
significantly inhibited the DNA relaxation activity of
DNA topoisomerase I, similarly to the positive control
drug, camptothecin. The results may indicate that the
compounds inhibit cell proliferation by the suppression
of DNA topoisomerase I action during replication. DNA
topoisomerase I is a nuclear enzyme that plays essential
roles in controlling the topological state of DNA to
facilitate and remove barriers for vital cellular functions,
including DNA replication and repair. Therefore, DNA
topoisomerase I is an important target for anticancer
agents.
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4. Discussion
Although there has been promising progress in cancer
research and the development of various anticancer
drugs for chemotherapy, about 8.2 million cancer deaths
were recorded in 2012 alone (http://globocan.iarc.fr/
Pages/fact_sheets_cancer.aspx). Many cancer drugs have
been withdrawn because of serious side effects, a loss
of sensitivity to these drugs, and limited use for various
tumor types. Therefore, the development of novel drugs
with universal anticancer activity and no side effects is still
important. The discovery of cisplatin (Kelland et al., 2007)
resulted in the development and use of novel metallodrugs
such as carboplatin, oxaplatin, and NAMI-1 in medicine
(Gielen and Tiekink, 2005).
In the present study, the anticancer potential, cytotoxic
activity, and mechanisms of action of newly synthesized
metal complexes AN1 and AN7 were investigated on
several tumor cell lines, such as HeLa, HT29, and C6.
The reason we chose these tumor cell lines was the higher
incidence, prevalence, and mortality of cervical, colon, and
brain cancers in the world. The results of cell proliferation
assay showed that these 2 metal compounds were
significantly more antiproliferative than 5FU (Figure 1)
against tumor cell lines but not nontumorigenic Vero cell
lines, indicating their anticancer potential, as in previous
studies (Iqbal et al., 2013; Medvetz et al., 2008; Wang et
al., 2010). It is known that cisplatin-like metallodrugs
inhibit cell proliferation by binding to cell DNA; however,
it is not clear yet whether AN1 and AN7 bind cell DNA.
In addition, AN1 and AN7 complexes were as cytotoxic
as 5FU against all tumor cell lines tested at their IC50
concentrations (Figure 2). Therefore, we suggest that these
compounds may have cytostatic potential rather than
cytotoxic potential. It is very clear that the cytotoxicity
of AN1 and AN7 against nontumorigenic Vero cells was
significantly low.
It is known that AN1 and AN7 complexes contain the
ligand [Ag(CN)2]1-, a very toxic compound against both
tumorigenic and normal cells. Therefore, we compared the
antiproliferative and cytotoxic activities of AN1, AN7, and
the ligand to reveal the contribution of the ligand to the
activities of AN1 and AN7. As shown Figures 1 and 2, the
antiproliferative and cytotoxic activities of AN1 and AN7
were significantly lower than that of the ligand, indicating
that the extreme cytotoxicity of [Ag(CN)2]1- decreased
to safe levels in AN1 and AN7, as reported by Batarseh
(2013).
We tested the apoptotic potential of the compounds
on the HT29 cell line using TUNEL assay to clarify their
mechanism of action for their antiproliferative activity.
As illustrated in Figure 3, the TUNEL results clearly show
that the AN1 and AN7 significantly induced apoptosis in
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Figure 3. Fluorescence and phase-contrast images of the HT29 cancer cells treated with test and control
compounds after TUNEL assay. TUNEL-positive cell nuclei were observed in brilliant green under fluorescence
(A-AN1, B-AN7, C-NC (negative control), and D-PC (positive control)) and phase contrast (A′-AN1, B′-AN7,
C′-NC (negative control), and D′-PC (positive control)).
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Figure 4. DNA topoisomerase I inhibitory activity of AN1 and AN7. A significant
increase in linear DNA and reduction of supercoiled DNA was observed with IC50
concentrations of AN1 and AN7. Lane 1: Supercoiled marker DNA; Lane 2: Relaxed
marker DNA; Lane 3: Negative control (supercoiled DNA + Topo I); Lane 4: Positive
control (supercoiled DNA + Topo I + camptothecin); Lane 5: Supercoiled DNA + Topo
I + AN1; Lane 6: Supercoiled DNA + Topo I + AN7.

HT29 cells. It is known that enhanced antitumor efficacy
is associated with increased induction of apoptosis.
These findings indicated that AN1 and AN7 inhibit cell
proliferation by inducing apoptosis, as in previous studies
by Govender et al. (2013) and Gandin et al. (2013). In
addition, these complexes resulted in the DNA degradation
of cancer cell DNA (data not shown), indicating their
apoptotic potential. These results were somewhat similar
to those of previous studies by Zachariadis et al. (2004),
El-Din et al. (2011), Korany et al. (2013), Pettinari et al.
(2011), and Banti and Hadjikakou (2013).
DNA topoisomerases are very effective antitumor
targets because of their essential function of regulating
DNA topology during DNA replication and recombination
(Champoux, 2001). Several important topoisomerase
inhibitors such as camptosar, irinotecan, and topotecan
have been used in routine clinical practice. In order
to understand whether the antiproliferative activity
of these compounds involves the inhibition of DNA
topoisomerases, we investigated the effects of AN1 and AN7
on the topoisomerase I-mediated relaxation of supercoiled
plasmid (pHOT1) DNA. The results revealed that the
IC50 concentrations of AN1 (containing Cd) and AN7
(containing Ni) inhibited almost all the DNA relaxation

activity of topoisomerase I, similarly to camptothecin
(Figure 4), indicating their antitopoisomerase potential for
use as novel topoisomerase inhibitors. Similarly to Wu’s
(2011) results, these findings may also indicate the binding
of these complexes not only to topoisomerase I, but also
to other proteins. It was reported by Hall et al. (1997) that
nickel(II) complexes of thiosemicarbazones significantly
inhibited topoisomerase II. Similarly, Prabhakaran et
al. (2011) showed that Ni(II) complexes containing
N-substituted thiosemicarbazones considerably inhibited
topoisomerase II.
In conclusion, our results have demonstrated that
metal complexes AN1 and AN7 are potent anticancer
drug candidates with higher antiproliferative, low
cytotoxic, strong apoptosis-inducing, and effective DNA
topoisomerase inhibitory characteristics. However, further
in vitro and in vivo studies need to be performed to verify
their anticancer drug potential.
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